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Abstract: In the present study, we aimed to preincubate MCF-10A cells with pioglitazone 
and/or serum-rich growth media and to determine adhesive and non-adhesive interactions 
of the preincubated MCF-10A cells with BT-474 cells. For this purpose, the MCF-10A 
cells were preincubated with pioglitazone and/or serum-rich growth media, at appropriate 
concentrations,  for 1 week.  The MCF-10A cells  preincubated with  pioglitazone and/or 
serum-rich  growth  media  were  then  co-cultured  adhesively  and  non-adhesively  with  
BT-474  cells  for  another  week.  Co-culture  of  BT-474  cells  with  the  preincubated  
MCF-10A cells, both adhesively and non-adhesively, reduced the growth of the cancer 
cells.  The  inhibitory  effect  of  the  preincubated  MCF-10A  cells  against  the  growth  of  
BT-474 cells was likely produced by increasing levels of soluble factors secreted by the 
preincubated MCF-10A cells into the conditioned medium, as immunoassayed by ELISA. 
However, only an elevated level of a soluble factor distinguished the conditioned medium 
collected from the MCF-10A cells preincubated with pioglitazone and serum-rich growth 
medium  than  that  with  pioglitazone  alone.  This  finding  was  further  confirmed  by  the 
induction of the soluble factor transcript expression in the preincubated MCF-10A cells, as 
determined using real-time PCR, for the above phenomenon. Furthermore, modification of 
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the MCF-10A cells through preincubation did not change the morphology of the cells, 
indicating that the preincubated cells may potentially be injected into mammary fat pads to 
reduce cancer growth in patients or to be used for others cell-mediated therapy. 
Keywords: adhesive and non-adhesive cell interaction; cell growth; human breast cancer; 
pioglitazone; serum-rich growth medium; tumourigenic and non-tumourigenic cells 
 
1. Introduction 
The peroxisome proliferator-activated receptor-gamma (PPARγ) ligands, such as pioglitazone, have 
been  demonstrated  to  have  therapeutic  value  for  human  breast  cancer  treatment  [1–3].  Although 
pioglitazone has been demonstrated not to induce apoptosis in both estrogen receptor (ER)-positive 
(MCF-7) and ER-negative (MDA-MB-231) tumourigenic human breast cells, as determined in ours 
(data not shown) and other studies [4], the use of pioglitazone in human breast cancer research remains 
valuable to be investigated. According to previous studies, pioglitazone demonstrates anti-metastatic 
effects on the highly invasive tumourigenic human breast cells, MDA-MB-231, by targeting the cells 
invasive  behaviour  [1].  Moreover,  pioglitazone,  as  well  as  rosiglitazone,  also  have  better  toxicity 
profiles  than  other  thioglitazones  (TZDs),  as  determined  in  our  present  study  (data  not  shown). 
However, the effects of pioglitazone on non-tumourigenic human breast cells, such as MCF-10A cells, 
have not yet been demonstrated. MCF-10A cells may also respond differently to the pioglitazone in 
serum-rich growth medium. Indeed, the interaction of the MCF-10A cells preincubated (modified) 
with  pioglitazone and/or serum-rich  growth  media and then co-cultured  with  tumourigenic human 
breast cells, such as MDA-MB-231 and BT-474, has never been demonstrated previously. 
MCF-10A cells, which are derived from an adherent human breast cell population of a Caucasian 
patient carrying fibrocystic disease, are a non-tumourigenic human breast epithelial cell line. The cells 
are widely used for breast cancer research as a control in comparison to tumourigenic human breast 
cells mainly due to the cells’ poorly-differentiated and hormone-independent characteristics [5]. In the 
present study, the adhesive and non-adhesive interactions of pioglitazone and/or serum-rich growth 
media  preincubated  MCF-10A  cells  with  BT-474  cells  were  determined.  The  study  aimed  to  
(1) preincubate MCF-10A cells with pioglitazone and/or serum-rich growth media, and (2) determine 
the adhesive and non-adhesive interactions of the above preincubated MCF-10A cells with BT-474 
cells  after  pioglitazone  and/or  serum  were  removed  from  the  growth  media.  The  soluble  factors 
secreted by the MCF-10A cells that were preincubated with pioglitazone and/or serum-rich growth 
media were also examined in this study. These soluble factors are believed to be proliferation-related 
growth factors. Expression of the soluble factors was then confirmed at the transcript level in the 
preincubated MCF-10A cells. It has been hypothesised that the preincubated MCF-10A cells might 
behave differently in co-culture with BT-474 cells compared with the non-preincubated MCF-10A 
cells. BT-474 cells were used instead of MDA-MB-231 in this study because BT-474 cells are also a 
highly invasive breast cancer cell line. More importantly, the BT-474 colonies are compact and can 
form multi-layered colonies on the MCF-10A feeder layer, unlike the MDA-MB-231 cells, which have 
a similar morphology as MCF-10A cells and never grow confluent (Figure 1). Int. J. Mol. Sci. 2012, 13  5609 
 
 
Figure 1. Co-culture of (A) MDA-MB-231 cells with MCF-10A cells, and (B) BT-474 
cells with MCF-10A cells. The BT-474 cells can easily be distinguished from MCF-10A 
cells,  whereas  the  epithelial-like  morphology  of  MDA-MB-231  cells  is  not  easily 
distinguishable. The pictures were taken at 40% cell confluence with 200x magnification, 
where  0.01  mm  was  equal  to  10  µm.  a:  MCF-10A  cells,  b:  MDA-MB-231  cells  and  
c: BT-474 cells. 
 
The  MCF-10A  cells,  for  this  purpose,  were  preincubated  with  pioglitazone  and/or  serum-rich 
growth  media,  at  a  specific  concentration,  for  1  week.  The  MCF-10A  cells  preincubated  with 
pioglitazone and/or serum-rich growth media were then co-cultured adhesively and non-adhesively 
with BT-474 cells for another week. For the adhesive interaction, the BT-474 cells were grown on the 
feeder layer of MCF-10A cells that had been preincubated with pioglitazone and/or serum-rich growth 
media, whereas for the non-adhesive interaction, the BT-474 cells were incubated with the conditioned 
media  of  MCF-10A  cells  preincubated  with  pioglitazone  and/or  serum-rich  growth  media.  The 
conditioned media were also used for ELISA immunoassays of soluble factors. Moreover, expression 
of soluble factors at the transcript level in the preincubated MCF-10A cells was determined using real-
time PCR. The morphologies of MCF-10A cells and BT-474 cells before and after cell-cell interaction 
were examined using Oil-red O or Hemacolor Quick staining, and inverted microscopy. The study may 
provide useful information regarding the effects of pioglitazone and serum-rich growth medium on 
MCF-10A cells preincubation in which the preincubated MCF-10A cells are hypothesised to have 
growth inhibitory effects on breast cancer cells. The preincubated MCF-10A cells may have potential 
to be used as cell-mediated therapy for human breast cancers as well as for other malignancies. 
2. Results and Discussion 
2.1. The Viability of MCF-10A Cells Incubated with Pioglitazone-Containing Growth Medium 
Optimisation  of  the  concentration  of  pioglitazone  in  the  growth  medium  that  modified  the  
MCF-10A cells while allowing the MCF-10A cells to grow efficiently was performed, as described in 
Section 4.2. As shown in Figure 2, incubation of MCF-10A cells in the growth medium supplemented 
with 20 µM of pioglitazone for 1 week allowed 84.5% of the cells to grow, when compared to the cells 
which were incubated with growth medium only (control). However, increasing the concentration of 
pioglitazone in the growth medium to 40 µM significantly reduced the viability of the MCF-10A cells Int. J. Mol. Sci. 2012, 13  5610 
 
 
to 74.0% (p < 0.05), when compared to the control. This effect was only observed after the MCF-10A 
cells were incubated with the appropriate concentration of pioglitazone for 1 week. Thus, 20 µM, as 
determined in this preliminary study, was the optimum concentration of pioglitazone to be added to the 
growth medium to preincubate the MCF-10A cells for subsequent experiments. 
Figure  2.  Viability  of  MCF-10A  cells  incubated  with  increasing  concentrations  of 
pioglitazone  in  the  growth  medium.  One  thousand  cells  were  used  as  the  input  for 
incubation, and the incubation was carried out for 1 week. The values are expressed as 
mean ±  SD from 3 replicates. * p < 0.05 was denoted as statistically significant. 
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2.2. The Growth of MCF-10A Cells Incubated with Serum-Rich Growth Medium 
In contrast, Figure 3 shows the growth of MCF-10A cells in the growth medium supplemented with 
an  increasing  concentration  of  serum.  Incubation  of  MCF-10A  cells  in  the  growth  medium 
supplemented with different concentrations of serum for 1 week increased the growth of the cells. This 
finding was observed when the MCF-10A cells were incubated with the growth media supplemented 
with 20% and 30% of serum, where the growth of the cells was found to be 52.4% (p < 0.01) and 
81.7% (p < 0.001), respectively, when compared to the cells incubated with growth medium only 
(control).  However,  the  growth  of  the  MCF-10A  cells  decreased  to  21.4%  when  the  cells  were 
incubated with the growth medium supplemented with 40% of serum. Therefore, 30% of serum was 
the  optimum  concentration  of  serum  to  be  added  to  the  growth  medium  for  the  preincubation  of  
MCF-10A cells. The growth media supplemented with 20 µM of pioglitazone and/or 30% of serum, 
which modified the MCF-10A cells while allowing the cells to grow efficiently, were used for the 
preincubation of MCF-10A cells. The growth media containing pioglitazone and/or serum, for the 
subsequent experiments, were then formulated as below: Culture Condition 1 as cells preincubated 
with growth medium only, Culture Condition 2 as cells preincubated with growth medium containing 
30% of serum only, Culture Condition 3 as cells preincubated with growth medium containing 20 µM 
of pioglitazone only and Culture Condition 4 as cells preincubated with growth medium containing 
30% of serum and 20 µ M of pioglitazone. The MCF-10A cells were preincubated with respective 
culture condition for 1 week. The conditioned media of the preincubated MCF-10A cells was then Int. J. Mol. Sci. 2012, 13  5611 
 
 
collected and used for non-adhesive interaction study whereas the preincubated MCF-10A cells were 
harvested and used for soluble factor transcript expression analysis (Section 4.3). 
Figure 3. Growth of MCF-10A cells incubated with increasing concentrations of serum in 
the growth medium. One thousand cells were used as the input for incubation, and the 
incubation was carried out for 1 week. Each value was calculated as the % of incubated 
cells  when compared to  control  cells. The values  were expressed as  mean ±  SD from  
3 replicates. ** p < 0.01 and *** p < 0.001 were denoted as statistically significant. 
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2.3. The Morphology of MCF-10A Cells Preincubated with Pioglitazone and/or Serum-Rich  
Growth Media 
Figure 4 shows the MCF-10A cells that were preincubated with pioglitazone and/or serum-rich 
growth media for 1 week. The preincubated MCF-10A cells showed little or no morphological changes, 
and no changes in aggregation status after the MCF-10A cells were preincubated with the different 
culture conditions, indicating that the preincubated MCF-10A cells may have undergone modification 
but  were  still  able  to  grow  efficiently  in  the  cell  culture  conditions.  This  finding  indicated  that 
preincubating the MCF-10A cells with pioglitazone and/or serum-rich growth media did not harm the 
original structure of the cells. The MCF-10A cells looked more compact in Figure 4B were due to 
overlapping of the cells. Int. J. Mol. Sci. 2012, 13  5612 
 
 
Figure 4. The morphologies of MCF-10A cells preincubated with (A) Culture Condition 1; 
(B)  Culture  Condition  2;  (C)  Culture  Condition  3;  and  (D)  Culture  Condition  4.  One 
hundred cells were used as the input for incubation, and the incubation was carried out for 
1 week. The cells were stained with Oil Red O Staining. The pictures were taken with 200×  
magnification,  where  0.01  mm  was  equal  to  10  µm.  Arrow  a,  b,  c  and  d  denote  the  
MCF-10A cells preincubated with Culture Condition 1, 2, 3 and 4, respectively, whereas e 
denotes the BT-474 cells grown on the preincubated MCF-10A feeder layers. 
 
2.4. The Adhesive Interaction of BT-474 and MCF-10A Cells Preincubated with Pioglitazone and/or 
Serum-Rich Growth Media 
The adhesive interaction study found that different size of BT-474 colonies formed on the feeder 
layer of MCF-10A cells that had been preincubated with pioglitazone and/or serum-rich growth media, 
after 2 weeks of incubation (Table 1). For this study, only large BT-474 colonies (100%) were grown 
on the feeder layer of MCF-10A cells that had been preincubated with Culture Condition 1 (Figure 5).  Int. J. Mol. Sci. 2012, 13  5613 
 
 
Table  1.  Percentage of  BT-474 colonies grown on the feeder layer of MCF-10A cells 
preincubated with pioglitazone and/or serum-rich growth media for 2 weeks. A total of  
20  cells/mL  of  BT-474  was  used  as  the  input  for  all  culture  conditions.  Data  were 
calculated as the % of colony number, according to the size, per total number of colonies 
formed on the preincubated MCF-10A feeder layer. The experiments were repeated 3 times 
to confirm reproducibility of the results, and a representative result is shown below. 
Culture 
Condition 
Large cell 
colony 
Moderate cell 
colony 
Small cell 
colony 
1 (control)  100.0%  -  - 
2  30.0%  20.0%  50.0% 
3  18.2%  27.3%  54.5% 
4  -  20.0%  80.0% 
Figure 5. The BT-474 colonies on the feeder layer of MCF-10A cells preincubated with 
pioglitazone and/or serum-rich growth media. (A)  Large BT-474 colonies in this study 
were  denoted  as  a  cell  population  of  about  1–2  mm  diameter  on  the  preincubated  
MCF-10A feeder layer; (B) moderate BT-474 colonies were defined as a cell population of 
about 0.5 mm diameter on the preincubated MCF-10A feeder layer; and (C) small BT-474 
colonies  were  defined  as  a  cell  population  of  less  than  0.2  mm  diameter  on  the 
preincubated  MCF-10A  feeder  layer.  The  pictures  were  taken  with  40×   magnification, 
where 0.01 mm was equal to 10 µm. 
 
However,  when  the  BT-474  cells  were  grown  on  the  MCF-10A  feeder  layer  that  had  been 
preincubated with Culture Conditions 2–4 for 2 weeks, the size of the BT-474 colonies (growth) was 
found  to  be  smaller.  The  BT-474  cells  that  were  grown  on  the  feeder  layer  of  MCF-10A  cells 
preincubated with Culture Condition 2 for 2 weeks were observed to form about 30.0% large colonies, 
20.0%  moderate  colonies  and  50.0%  small  colonies  on  the  preincubated  MCF-10A  feeder  layer. 
Similarly, the BT-474 cells that were grown on the feeder layer of MCF-10A cells preincubated with 
Culture Condition 3 formed about 18.2% large cell colonies, 27.3% moderate cell colonies and 54.5% 
small cell colonies on the preincubated MCF-10A feeder layer. Surprisingly, a remarkable effect was 
found when the BT-474 cells were grown on the feeder layer of MCF-10A cells preincubated with 
Culture Condition 4, where only 20% moderate cell colonies  and 80% small cell colonies on the 
preincubated  MCF-10A  feeder  layer  were  observed.  Few  or  no  morphological  changes,  and  no 
changes in aggregation status of the BT-474 cells were observed when the cells were grown on the 
feeder layer of MCF-10A cells preincubated with any of the tested culture conditions. The cancer cells Int. J. Mol. Sci. 2012, 13  5614 
 
 
were incubated for 2 weeks because the growth of the BT-474 cells on the preincubated MCF-10A 
feeder layer was only clearly and significantly observed after 2 weeks of incubation.  
2.5. The Non-Adhesive Interaction of BT-474 Cells and MCF-10A Cells Preincubated with 
Pioglitazone and/or Serum-Rich Growth Media 
The non-adhesive interaction study found that the incubation of BT-474 cells with the conditioned 
media of MCF-10A cells preincubated with pioglitazone and/or serum-rich growth media for 2 weeks 
reduced  the  growth  of  the  cancer  cells  (Figure  6).  In  this  study,  the  growth  of  the  BT-474  cells 
incubated with the conditioned medium of MCF-10A cells preincubated with Culture Condition 1 was 
denoted as 100%. 
Figure 6. Growth of BT-474 cells incubated with the conditioned media of MCF-10A cells 
preincubated  with  Culture  Condition  1,  Culture  Condition  2,  Culture  Condition  3  and 
Culture Condition 4. One hundred cells were used as the input for incubation, and the 
incubation was carried out for 2 weeks. Each value was calculated as the % of sample cells 
relative to the control cells. The values were expressed as mean ±  SD from 3 replicates.  
** p < 0.01 and *** p < 0.001 were denoted as statistically significant. 
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The growth of BT-474 cells that were incubated with the conditioned media of MCF -10A cells 
preincubated  with  Culture Condition 2 and Culture Condition 3 ,  for 2 weeks,  was about 86.79%  
(p  >  0.05)  and  32.08%  (p  <  0.01),  respectively,  when  compared  to  the  growth  of  BT-474  cells 
incubated with the conditioned medium of MCF-10A cells preincubated with Culture Condition 1.  
In contrast, the growth of BT-474 cells incubated with the conditioned medium of MCF-10A cells 
preincubated  with  Culture  Condition  4,  for  2  weeks,  was  only  about  7.55%  (p  <  0.001),  when 
compared to the growth of BT-474 cells incubated with the conditioned medium of MCF-10A cells 
preincubated with Culture Condition 1. Moreover, similar to the adhesive interaction as mentioned 
above, despite the effect on the growth of the BT-474 cells, little or no morphological changes, and no 
changes in aggregation status were observed in the BT-474 cells when the cancer cells were incubated Int. J. Mol. Sci. 2012, 13  5615 
 
 
with the conditioned media of MCF-10A cells preincubated with any of the tested culture conditions 
(Figure 7). This finding indicated that the factors causing the BT-474 growth inhibition were likely 
presented in the medium and therefore could be detected in the conditioned media of MCF-10A cells 
preincubated with various culture conditions. These factors are likely affected only the growth of the 
BT-474 cells, but have little effect on the morphologies of both MCF-10A cells and BT-474 cells. 
Thus, the subsequent study was conducted to determine the levels of soluble factors existing in the 
conditioned media of preincubated MCF-10A cells using ELISA. These soluble factors are believed to 
have an impact on the cancer cell growth.  
Figure 7. The morphologies of BT-474 cells preincubated with (A) Culture Condition 1; 
(B)  Culture  Condition  2;  (C)  Culture  Condition  3;  and  (D)  Culture  Condition  4.  One 
hundred cells were used as the input for incubation, and the incubation was carried out for 
2 weeks. The cells were stained with Hemacolor Quick Staining. The pictures were taken 
with 200 ×  magnification, where 0.01 mm was equal to 10 µm. 
 
2.6. The Levels of Soluble Factors in the Conditioned Media of Preincubated MCF-10A Cells 
As shown above, the non-adhesive interaction of BT-474 cells with MCF-10A cells that have been 
preincubated with pioglitazone and/or serum-rich growth media produced similar results as the studies 
of BT-474 cells interacting with the preincubated MCF-10A cells under adhesive conditions; both 
interactions reduced the growth of BT474 cells. This finding led us to hypothesise that the inhibition of 
BT-474 growth was likely due to the secretion of some soluble factors by the preincubated MCF-10A 
cells.  These  soluble  factors  that  could  be  detected  in  the  conditioned  media  of  the  preincubated  
MCF-10A cells were likely prohibited the BT-474 cells from growing. Therefore, it is important to 
determine the levels of the soluble factors (proteins) that are present in the conditioned media using Int. J. Mol. Sci. 2012, 13  5616 
 
 
ELISA.  The soluble factors to be assayed in this study, soluble factors a–d, are  reported to have 
proliferation-related effects on cancer cell growth, as reported in a few previous studies [6–13]. 
Our  study  found  that  the  soluble  factors  secreted  by  the  preincubated  MCF-10A  cells  in  the 
conditioned media varied depending on the culture conditions used in this study (Figure 8). The same 
levels of soluble factors were detected in the conditioned media of MCF-10A cells preincubated with 
Culture Conditions 1 and 2, whereas elevated levels of soluble factor a, soluble factor c and soluble 
factor d were found in the conditioned media of MCF-10A cells preincubated with Culture Conditions 
3 and 4. However, a slightly higher level of soluble factor c was only found in the conditioned media 
of  MCF-10A  cells  preincubated  with  Culture  Condition  4,  thus  displaying  a  difference  from  the 
Culture Condition 3. This elevated level of soluble factor c was likely resulted from the additional 30% 
of serum in the growth medium for the preincubation with Culture Condition 4 and caused better 
growth inhibitory effect on BT-474 rather than the use of pioglitazone alone. However, little or no 
change in the level of soluble factor b or CCL5 was found in the conditioned media of MCF-10A cells 
preincubated  with  all  of  the  tested  culture  conditions,  although  the  overexpression  of  CCL5  was 
reported to delay tumour growth as well as to increase tumour cell infiltration [14]. 
Figure 8. The expression levels of (A) soluble factor a, (B) soluble factor b, (C) soluble 
factor c, and (D) soluble factor d in the conditioned media of MCF-10A cells preincubated 
with pioglitazone and/or serum-rich growth media. The levels of the soluble factors were 
assayed by ELISA. The levels of soluble factors in the conditioned medium of MCF-10A 
cells  preincubated  with  Culture  Condition  1  was  defined  as  100%.  The  values  were 
expressed as mean ±  SD from 3 replicates. * p < 0.05, ** p < 0.01 and ** p < 0.001 were 
denoted as statistically significant. 
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Figure 8. Cont.  
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2.7. The Transcript Levels of Soluble Factors in the Preincubated MCF-10A Cells 
Consistent with the ELISA results, similar levels of gene transcripts that correlated to those soluble 
factors in the conditioned media were also found in the MCF-10A cells preincubated with Culture 
Conditions 1–4, using real-time PCR (Figure 9). For this study, high expression level of soluble factor 
a transcript were found in the MCF-10A cells preincubated with Culture Conditions 3 and 4. These 
levels were 3.7-fold (p < 0.05) and 2.7-fold (p < 0.05) higher, respectively, when compared to the 
MCF-10A cells preincubated with Culture Condition 1. However, the soluble factor a transcript level 
in the MCF-10A cells preincubated with Culture Condition 2 was only 0.5-fold increased (p > 0.05), 
when the same comparison was made. The soluble factor c transcript was also found to be increased in 
the  preincubated  MCF-10A  cells.  The  soluble  factor  c  transcript  levels  in  the  MCF-10A  cells 
preincubated with Culture Conditions 2, 3 and 4 were 2.0-fold (p > 0.05), 3.6-fold (p < 0.05) and  
5.6-fold (p < 0.01) higher than the MCF-10A cells preincubated with Culture Condition 1, respectively. 
However, only the MCF-10A cells preincubated with Culture Condition 4 produced the most elevated 
soluble factor c transcript level, which differentiated the MCF-10A cells preincubated with this culture 
condition from the MCF-10A preincubated with Culture Condition 2 and Culture Condition 3. This 
phenomenon  confirmed  that  the  elevated  level  of  soluble  factor  c  was  likely  contributed  by  the 
additional  30%  of  serum  in  the  growth  medium  for  the  preincubation  and  caused  better  growth 
inhibitory effect on BT-474 cells rather then the use of either serum-rich or pioglitazone alone in the 
growth medium. In contrast, while soluble factor d levels were found to be elevated in the conditioned 
media of preincubated MCF-10A cells, increased gene expression of soluble factor d was not detected 
in the preincubated MCF-10A cells using real-time PCR. The soluble factor d, in this study, is believed 
as VEGF. Consistently, little or no effect on the soluble factor b or CCL5 transcript was found in the 
preincubated MCF-10A cells in all culture conditions tested in this study. Int. J. Mol. Sci. 2012, 13  5618 
 
 
Figure 9. The transcript levels of (A) soluble factor a, (B) soluble factor b, (C) soluble 
factor c and (D) soluble factor d in MCF-10A cells preincubated with pioglitazone and/or 
serum-rich growth media. These genes’ transcripts were analysed using real-time PCR. 
Each value was calculated as a percentage of fold change in expression, in the preincubated 
MCF-10A  cells.  The  gene  transcript  in  the  MCF-10A  cells  preincubated  with  Culture 
Condition  1  was  defined  as  100%.  The  values  were  expressed  as  mean  ±   SD  from  
3 replicates. * p < 0.05 and ** p < 0.01 were denoted as statistically significant. 
 
3. Discussion 
Our study demonstrated that (1) the adhesive interaction of BT-474 cells with the feeder layer of 
MCF-10A cells preincubated with pioglitazone and/or serum-rich media reduced the growth of the 
cancer  cells,  and  (2)  the  non-adhesive  interaction  of  BT-474  cells  with  the  conditioned  media  of  
MCF-10A cells preincubated with pioglitazone and/or serum-rich media also reduced the growth of the 
cancer cells. The most promising inhibitory effect on BT-474 growth was observed when the cancer 
cells interacted adhesively and non-adhesively with the feeder layer or the conditioned medium of 
MCF-10A  cells  preincubated  with  serum-rich  growth  medium  containing  pioglitazone,  which  was 
followed by the feeder layer or the conditioned medium of MCF-10A cells that were incubated with 
pioglitazone-containing medium. As the adhesive and non-adhesive interaction studies of BT-474 cells 
with the preincubated MCF-10A cells produced a similar inhibitory effect on the cancer cells, this Int. J. Mol. Sci. 2012, 13  5619 
 
 
finding indicated that the inhibition of BT-474 growth caused by the preincubated MCF-10A cells can 
occur over some distance (medium) without the need to interact directly. Moreover, the inhibitory 
effect was likely caused by the secretion of certain soluble factors from the MCF-10A cells into the 
conditioned medium after the preincubation, where the soluble factors were believed to prohibit the 
BT-474 cells from growing. These soluble factors could be detected by ELISA in the conditioned 
media of the preincubated MCF-10A cells. 
The ELISA immunoassays showed that the conditioned media of MCF-10A cells that had been 
preincubated with growth medium containing pioglitazone alone or with a combination of pioglitazone 
and serum-rich growth medium secreted higher levels of soluble factor a, soluble factor c and soluble 
factor  d  into  the  conditioned  media.  These  soluble  factors  in  the  conditioned  media  were  likely 
inhibited the growth of BT-474 cells when the cancer cells interacted adhesively or non-adhesively 
with the preincubated MCF-10A cells. The preincubated MCF-10A cells secreted soluble factor a, 
soluble factor c and soluble factor d into the conditioned media were likely increased survival of the 
MCF-10A cells against the growth of the cancer cells. Besides, high levels of soluble factor a and 
soluble factor c transcripts were also detected in the MCF-10A cells preincubated with pioglitazone 
and/or serum-rich growth media using real-time PCR. Although the soluble factor a and soluble factor 
c were over-expressed in the preincubated MCF-10A cells, only a higher level of soluble factor c was 
found in the MCF-10A cells preincubated with serum-rich growth medium containing pioglitazone. 
This phenomenon implicated the secretion of high level of soluble factor c as the factor causing the 
most promising inhibitory effect on BT-474 growth when the cancer cells interacted with the feeder 
layer or the conditioned medium of the MCF-10A cells that were incubated with serum-rich growth 
medium  containing  pioglitazone  than  that  with  the  feeder  layer  or  the  conditioned  medium  of  
MCF-10A cells that were incubated with pioglitazone-containing growth medium only. The soluble 
factor a and soluble factor c that were overexpressed in the conditioned media of the preincubated 
MCF-10A are believed as CCL2 and IL-6, respectively. 
CCL2, also  known  as  MCP-1, is  a CC-chemokine that is  chemotactic for monocytes, memory  
T-cells and NK cells [15,16]. It is expressed by a wide variety of cancer types. A large number of 
studies have demonstrated that CCL2 generally facilitates tumour progression where this phenomenon 
can be observed in pancreatic [17], breast [18,19] and gastric cancers [20]. However, our present study 
demonstrated that an increased level of CCL2 inhibited the growth of BT-474 cells, paving a new 
discussion on this topic. In addition, IL-6 is an interleukin that plays a key role in the pathophysiology 
of several cancers and various inflammatory disorders of the immune system [21]. Its over-expression 
has been implicated in the tumourigenesis of multiple myeloma, ovarian, renal cell, prostate, cervical 
and breast  carcinomas  [22–25].  In a previous study, CCL2 was  hypothesised to  contribute to  the 
development of lung fibrosis by reducing IL-6 level [26]. However, the precise mechanisms of action 
of both CCL2 and IL-6 in the preincubated MCF-10A cells are not yet elucidated. As the preincubated 
MCF-10A cells may have potential to be used for cell-mediated therapy, both CCL2 and IL-6 secreted 
by the preincubated MCF-10A cells should carefully be analysed in our future research. Perhaps, novel 
finding, such as new CCL2 and IL-6 isoforms, may be identified in this part of the study.  
For the first time, this study found that the over-expression of CCL2 and IL-6 in the conditioned 
medium of the preincubated MCF-10A cells can reduce the growth of BT-474 cells. However, the 
precise anti-tumoural effect of both CCL2 and IL-6 on BT-474 growth remains unclear. Perhaps, there Int. J. Mol. Sci. 2012, 13  5620 
 
 
are some additional unknown factors in the conditioned media that inhibit the growth of BT-474 cells. 
CCL2,  which  stimulates  IL-6  production,  may  contribute  to  the  development  of  fibrosis  in  the 
preincubated  MCF-10A  cells  and  should  also  be  taken  into  account  [26].  Taken  together,  the 
interaction of the preincubated MCF-10A cells with BT-474 cells only reduced the growth of the 
cancer cells. Little or no morphological changes and no changes in the aggregation status of both the 
MCF-10A and  BT-474  cells  were observed during the interaction.  This  work may provide useful 
information  about  the  factors  that  may  prevent  the  tumorigenic  cells  from  growing  on  the  
non-tumourigenic feeder layer or that may prevent the metastatic cancer cells from migrating to the 
non-tumourigenic tissue or organ. The MCF-10A cells that have been preincubated with pioglitazone 
and/or serum-rich growth media may have potential to be used as a component for cell-mediated 
therapy for human breast cancers as well as for other malignancies. For example, the preincubated 
MCF-10A cells, that exhibited anti-cancer growth properties, may be injected in the mammary fat pad 
in  order  to  treat  the  cancer  patients  or  to  be  used  for  others  cell-mediated  therapy.  Although  the 
challenges facing how the modified MCF-10A cells can be injected in the human body are formidable, 
it is likely possible. We are aware also of the concern that the preincubated cells and the derived tissue 
would be rejected by the patient's immune system. However, based on current proposed solutions to 
this incompatibility problem worldwide, such as generating large banks of stem cell lines that perfectly 
match the patient or genetically engineering stem cells to reduce immune rejection, it may provide 
essentially convincing evidence and prove the complex scientific endeavor. A similar approach has 
been utilized by AdiStem Ltd., a biotechnology company, to repair tissues in the human body. For this, 
adipose  tissue-derived  stem  cells  from  a  patient  are  treated  and  activated  with  AdiStem  solution 
(activator). The activated stem cells are then returned to the patients via a standard IV drip. 
4. Experimental Section  
4.1. Culturing of MCF-10A and BT-474 Cell Lines 
The MCF-10A cell line was routinely cultured with growth medium for non-tumourigenic human 
breast cells (low glucose Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 10% 
fetal bovine serum (FBS), 100 U/mL penicillin and 100 mg/mL streptomycin with stable glutamine 
and  Na-pyruvate),  whereas  the  BT-474  cell  line  was  cultured  using  the  growth  medium  for 
tumourigenic  human  breast  cells  (high  glucose  DMEM  supplemented  with  10%  FBS,  100  U/mL 
penicillin and 100 mg/mL streptomycin). An optional supplement of 1×  Mycokill was added to both 
growth media to prevent mycoplasma contamination. The cell lines were maintained at 37 ° C in a 
humidified atmosphere of 5% (v/v) CO2. The growth media for MCF-10A cells and BT-474 cells were 
changed every 2–3 days. The cell lines were sub-cultured and maintained for subsequent experiments.  
4.2. Viability of MCF-10A Cells Incubated with Pioglitazone-Containing or Serum-Rich  
Growth Medium 
The viability of MCF-10A cells incubated with either pioglitazone-containing or serum (FBS)-rich 
growth medium was determined using trypan blue assay. The viability of the cells was determined in 
order to select the appropriate concentrations of pioglitazone and serum with which to preincubate the Int. J. Mol. Sci. 2012, 13  5621 
 
 
MCF-10A cells. For this assay, the MCF-10A cells were seeded at a density of 1.0 ×  10
3 cells/mL in a 
24-well culture plate. When the cells in each well reached approximately 70% confluency, increasing 
concentrations of pioglitazone (0–40 µM) or serum (10–40%) were added to the cells. The cells were 
then incubated in the culture conditions, as described above, for 1 week. DMSO (0.1%) was used as 
the diluent control for pioglitazone in this study. All control and experimental samples were cultured in 
triplicate. After 1 week, the cells were harvested using trypsin-EDTA solution. The harvested cell 
suspension (0.9 mL) from each well was then combined with 0.1 mL of Trypan Blue Solution, and the 
mixture was incubated at room temperature for 5 min. Living and dead cells were then counted using a 
haemocytometer and the viability (%) of the MCF-10A cells was calculated as below: 
Viability (%) = (number of unstained cells per quadrant/total cells per quadrant) ×  100  (i) 
Living cells were observed to exclude the dye (unstained cells), whereas dead cells took up the blue 
dye. The same method was used to calculate the viability of MCF-10A cells preincubated with growth 
media supplemented with 10–40% serum. The appropriate concentrations of pioglitazone and serum 
were selected so that their presence in the media modified the MCF-10A cells, but did not significantly 
decrease the viability of the MCF-10A cells. The concentrations of pioglitazone and serum used in this 
study  were  optimised  and  selected  as  described  in  Section  2.1  and  2.2.  After  that,  the  
pioglitazone-containing and serum-rich growth media used to preincubate the MCF-10A cells was 
prepared, as described in Table 2. 
Table  2.  Incubation  of  MCF-10A  cells  with  low  glucose  DMEM  growth  media 
supplemented  with  pioglitazone  and/or  serum  at  the  appropriate  concentrations,  as 
described in the Table, for 1 week. The concentrations of pioglitazone and serum used in 
this study were optimised as described in the results section. 
Culture Condition  Serum Concentration  Pioglitazone Concentration 
1 (control)  10% *
  - 
2  30%  - 
3  10% *  20 µM 
4  30%  20 µM 
* The FBS from growth medium only. 
4.3. Preparation of the Conditioned Media and MCF-10A Cells Preincubated with Pioglitazone and/or 
Serum-Rich Growth Media  
The  conditioned  media  and  MCF-10A  cells  preincubated  with  pioglitazone  and/or  serum-rich 
growth media were prepared by seeding 1.0 ×  10
4 cells/mL of MCF-10A cells in T-75-cm
2 cell culture 
flasks and the cells were maintained with low glucose DMEM growth medium, as described above, 
until the cells were 70–80% confluent. Next, the old growth medium was removed and the adherent 
MCF-10A feeder layer was carefully washed several times with prewarmed PBS before adding the 
appropriate concentration of pioglitazone and/or serum-rich supplemented growth media, as described 
in Table 2. The MCF-10A cultures were then incubated under the appropriate culture conditions for  
1 week. After 1 week of incubation, the pioglitazone and/or serum-rich supplemented growth media 
were removed, and the preincubated MCF-10A feeder layer, for all culture conditions, was carefully Int. J. Mol. Sci. 2012, 13  5622 
 
 
washed  again  several  times  with  prewarmed  PBS  before  fresh  growth  media  were  added  to  the  
MCF-10A feeder layer. The preincubated MCF-10A feeder layer was then incubated with the fresh 
growth medium again for 1 week. Following a week of incubation, the growth media, which is now 
described as conditioned media, for all culture conditions was collected in 15 mL falcon tubes. The 
conditioned media was centrifuged at maximum speed for 20 min to concentrate any particles or cell 
debris, and the supernatants were collected and used for non-adhesive interaction study with BT-474 
cells,  as  described  in  Section  4.5,  or  were  used  for  immunoassay,  as  described  in  Section  4.6.  
The preincubated MCF-10A cells were also monitored using Hemacolor Quik staining and inverted 
microscopy, or harvested for soluble factor transcript expression study, as described in Section 4.7.  
In brief, the preparations of the conditioned media and preincubated MCF-10A cells are outlined in 
Figure 10. 
Figure  10. Schematic of the conditioned media and MCF-10A cells preincubated with 
pioglitazone and/or serum-rich growth media preparations.  
 
4.4. Adhesive Interaction of BT-474 Cells and MCF-10A Cells Preincubated with Pioglitazone and/or 
Serum-Rich Growth Media 
The adhesive interaction or direct co-culture of BT-474 cells with MCF-10A cells preincubated 
with pioglitazone and/or serum-rich growth media was carried out by seeding 1.0 ×  10
3 MCF-10A 
cells/mL in a 4-well chamber slide. The cells were allowed to adhere overnight. The MCF-10A cells 
were then preincubated with pioglitazone and/or serum-rich growth media as described in Section 4.3. 
After  1  week,  the  growth  media  supplemented  with  pioglitazone  and/or  serum  was  removed,  the Int. J. Mol. Sci. 2012, 13  5623 
 
 
preincubated  MCF-10A  feeder  layer  was  carefully  washed  and  a  suspension  of  BT-474  cells  
(10 cells/well) was added to the preincubated MCF-10A feeder layer. The BT-474 cells were also 
cultured alone as control. After 2 weeks of incubation, the morphology and the number of BT-474 
colonies that grew on the preincubated MCF-10A cells were monitored and quantified using Oil Red O 
staining and inverted microscopy. The co-culture was repeated at least twice. 
4.5. Non-Adhesive Interaction of BT-474 Cells with MCF-10A Cells Preincubated with Pioglitazone 
and/or Serum-Rich Growth Media 
The  non-adhesive  interaction  or  indirect  co-culture  of  BT-474  cells  with  MCF-10A  cells 
preincubated  with  pioglitazone  and/or  serum-rich  growth  media  was  performed  by  incubating  the  
BT-474  cells  with  the  conditioned  media  of  preincubated  MCF-10A  cells  collected  from  Culture 
Conditions  1–4,  as  described  in  Section  4.3.  The  BT-474  cells,  for  this  experiment,  were  seeded  
(1.0 ×  10
2 cell/mL) and maintained with low glucose DMEM growth medium in a 12-well plate. After 
24 h of incubation, the old growth medium was removed and the conditioned media from Culture 
Conditions 1–4, was collected as described in Section 4.3, and added to the BT-474 cells. The BT-474 
cells were incubated in conditioned media for 2 weeks. Incubation of the BT-474 cells with each 
conditioned medium was performed in triplicate. After 2 weeks incubation, the BT-474 cells were 
trypsinised, and the viability of the cells was quantified using the trypan blue exclusion assay. The  
co-culture was repeated at least twice. 
4.6. Immunoassay of Soluble Factors in the Conditioned Media 
The levels of soluble factors a–d present in the conditioned media of preincubated MCF-10A cells 
were determined using commercially available ELISA kits. In these kits, antibodies specific for the 
proteins were precoated onto microtitre plates. The samples (conditioned media) were then added to 
the wells and allowed to react with the bound antibody for 2.5 h at room temperature. The unbound 
substances  were washed away  with  a Wash  Solution, according to  the manufacturer’s  instruction. 
Subsequently, an enzyme-linked antibody specific to the proteins was added to the wells. The antibody 
was incubated with the target for 1 h. Following another washing step, a substrate solution was added 
to the wells for colour development. The colour developed was proportional to the amount of protein 
present in the samples. The colour intensity was then measured using an ELISA reader at a wavelength 
of 450 nm, and the level of each specific protein in the conditioned media was calculated. The ELISA 
were performed in triplicate and repeated in at least 2 independent experiments. 
4.7. Analysis of Soluble Factor Transcript Expressions in the Preincubated MCF-10A Cells  
The total RNA was extracted from the preincubated MCF-10A cells using a commercially available 
total RNA extraction kit. The integrity of the total RNA extracted was confirmed by agarose gel 
electrophoresis,  and  the  purity  and  concentration  of  the  total  RNA  extracted  was  measured  by 
spectrophotometry.  Subsequently,  1.0  μg  of  RNA  was  reverse-transcribed  into  cDNA  using  a 
commercially available First Strand cDNA  Synthesis kit, and this cDNA was used to analyse the 
expressions of soluble factor transcripts in the preincubated MCF-10A cells by real-time PCR. Primers Int. J. Mol. Sci. 2012, 13  5624 
 
 
specific to these genes were designed using Primer Express 2.0 (Table 3), and the real-time PCR was 
performed using a Rotor Gene 600 PCR system, according to the manufacturer’s instruction. To do 
this, the reactions were carried out in a total volume of 25 µL, in optical reaction tubes that included 
SYBR Green Master Mix, 900 nM of each primer and cDNA as prepared above. The reaction program 
was then initiated at 95 C for 10 min to activate the enzyme, follow by 40 cycles of denaturation at  
95 ° C for 15 s, and primer annealing combined with extension stage was performed at 60 ° C for 1 min. 
The CT value of each  gene in  each unknown  sample was  normalised  to  β-actin, and the relative 
expression  level  of  each  gene,  as  well  as  the  fold  changes  in  gene  expression,  were  calculated, 
according to the manufacturer’s instruction. The PCR was performed in triplicate and repeated in at 
least 2 independent experiments. 
Table 3. Primer design for real-time PCR. 
Gene(s)  Sequence(s)  Amplicon 
(bp) 
Tm 
(° C) 
 
Soluble factor a 
Forward: 5'-GCTGTGATCTTCAAGACCATTGTG-3'   
123 
 
80  Reverse: 5'-AGTGAGTGTTCAAGTCTTCGGAGTT-3' 
 
Soluble factor b 
Forward: 5'-AGCCTCTCCCACAGGTACCAT-3'   
67 
 
85  Reverse: 5'-GGCAGTAGCAATGAGGATGACA-3' 
 
Soluble factor c 
Forward: CCAGTACCCCCAGGAGAAGATT   
104 
 
81  Reverse: CCGTCGAGGATGTACCGAAT 
 
Soluble factor d 
Forward: 5'-CGCAGCTACTGCCATCCAAT-3'   
81 
 
81  Reverse: 5'-TGGCTTGAAGATGTACTCGATCTC-3' 

β-actin 
Forward: 5'-CATTGCCGACAGGATGCA-3'   
102 
 
82  Reverse: 5'-CCGATCCACACGGAGTACTTG-3' 
4.8. Statistical Analysis 
All  graphs  and  all  statistical  calculations  were  generated  and  performed  using  GraphPad  4.01 
software. The experiments were repeated several times to confirm the reproducibility of the results. All 
values are expressed as the mean ±  SD. A p value less than 0.05 was regarded as statistically significant. 
5. Conclusions  
Our study has demonstrated that the MCF-10A cells that have been preincubated with pioglitazone 
and/or serum-rich growth media for 1 week were able to reduce the growth of BT-474 cells when the 
preincubated MCF-10A cells and BT-474 cells interacted with one another adhesively or non-adhesively. 
This  reduction  was  likely  due  to  the  overexpression  of  some  soluble  factors  in  the  preincubated  
MCF-10A cells. However, future studies are needed to understand the precise mechanisms of action 
for the soluble factors in the preincubated MCF-10A cells as well as the anti-tumoural effects of the 
preincubated MCF-10A cells on the growth of BT-474 cells. Int. J. Mol. Sci. 2012, 13  5625 
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